It has been called “the blockbuster drug of the century,” the holy grail of health care and the next great frontier in the search for a more responsive and cost-effective healthcare system. But is it a truly achievable goal, and will it really transform the way health care is delivered in the United States?
The Food and Drug Administration has declined to approve an experimental drug for schizophrenia and bipolar disorder developed by Forest Labs and Gedeon Richter, a Hungarian drug company, the two said Thursday.
While drug companies are developing treatments for a wide variety of diseases, the greatest amount of mid- to late-stage research and development activity is in cancer treatments, according to a new report.
Pharmacists traditionally have been one of the most underutilized members of the healthcare team, possibly because they hadn’t been officially recognized as part of that team. That, however, is about to change.
A bill that would implement federal tracking and tracing of drugs and strengthen federal regulations on pharmacy compounding has passed in the Senate and will go to President Barack Obama for his signature.
An experimental human papillomavirus vaccine made by Merck could offer a boost to the vaccine market, but the company will have to use effective marketing efforts to ensure uptake, according to a new study.
The value of drugs approved in the United States this year could reach almost $19 billion in sales five years after their launch, exceeding the value of drugs approved in 2012, according to a new report.